MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 1.23 and traded as low as GBX 1.22. MaxCyte shares last traded at GBX 1.24, with a volume of 678,902 shares traded.
MaxCyte Stock Down 0.8%
The stock has a market capitalization of £1.34 million, a price-to-earnings ratio of -0.03 and a beta of 1.13. The company has a quick ratio of 14.38, a current ratio of 12.39 and a debt-to-equity ratio of 9.70. The business’s 50-day moving average is GBX 1.24 and its two-hundred day moving average is GBX 1.02.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Further Reading
- Five stocks we like better than MaxCyte
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
